Moss, 26 October 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the third quarter of 2023.

Highlights

o Sales of MNOK 32.1 in 3Q23, up 39% vs 3Q22 (29% organic growth). Revenue of
MNOK 97.7 YTD 2023 up 33% (21% organic growth) vs YTD 2022.
 
o EBITDA of NOK 1.2 million in 3Q23 and NOK 4.3 million YTD 2023, compared to
EBITDA of NOK -6.1 million in 3Q22 and NOK -11.5 million YTD 2022.

o Cystatin C sales increased 90% in 3Q23 compared to 3Q22 and 39% YTD 2023 vs
YTD 2022.

o Launch of Gentian Retinol-Binding Protein (RBP) Immunoassay. A new CE-marked
turbidimetric instrument independent assay, with the key demand driver being the
aging population and lifestyle associated diseases and deficiencies. 

Webcast

Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
10.00 am, followed by a Q&A session. Join the webcast and submit questions via
the following link:

https://attendee.gotowebinar.com/register/7976233815452043612

The webcast will be available on the company website after the presentation. 

IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 26 October 2023 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.